Home › Daiichi Sankyo Submits Supplemental New Drug Application In Japan For LIXIANA (Edoxaban Tosilate Hydrate) For New Indications
 

Keywords :   


Daiichi Sankyo Submits Supplemental New Drug Application In Japan For LIXIANA (Edoxaban Tosilate Hydrate) For New Indications

2013-12-30 06:22:57| drugdiscoveryonline News Articles

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application (NDA) for its oral, once-daily direct factor Xa-inhibitor LIXIANA® (Edoxaban Tosilate Hydrate) for review by the Japanese Ministry of Health, Labour and Welfare

Tags: new japan application drug

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
18.05Eastern North Pacific Tropical Weather Outlook
18.05Atlantic Tropical Weather Outlook
17.05House Republicans release farm bill draft
17.05House Republicans release farm bill draft
17.05Union forming stalled in US Mercedes-Benz
17.05Johnson & Johnson Acquires Atopic Dermatitis Treatment Biotech Company
More »